Results 161 to 170 of about 3,657 (192)

Bedaquiline/delamanid

Reactions Weekly, 2021
openaire   +1 more source

[Expert consensus on clinical application of delamanid].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2022
Multidrug-resistant tuberculosis(MDR-TB) is a major problem in the prevention and treatment of tuberculosis worldwide, but the treatment success rate is low, and it is necessary to develop new anti-tuberculosis drugs and optimize treatment. Delamanid, a drug with good activity against MDR-TB, has been marketed in recent years.
openaire   +1 more source

Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid

Clinical Infectious Diseases, 2021
Ken Ohta, Satoshi Mitarai, Takashi Yoshiyama   +2 more
exaly  

Delamanid

Reactions Weekly, 2016
openaire   +1 more source

Delamanid

Drugs of the Future, 2013
openaire   +1 more source

Delamanid/linezolid

Reactions Weekly, 2020
openaire   +1 more source

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid

International Journal of Infectious Diseases, 2020
Tae Sun Shim, Kyung-Wook Jo, Doosoo Jeon   +2 more
exaly  

Bedaquiline/delamanid

Reactions Weekly, 2020
openaire   +1 more source

Delamanid/linezolid

Reactions Weekly, 2019
openaire   +1 more source

Delamanid (antituberculoso nuevo) síntesis

2022
Torres, Hector, La Parra, Mario González-De   +1 more
openaire   +1 more source